Return to homepagePandemic Pact

Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Mpox Vaccine

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N91019D00024-P00001-759102200024-2

Grant search

Key facts

  • Disease

    mpox

  • Start & end year

    2022
    2024

  • Known Financial Commitments (USD)

    $6,645,185

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    THERESA ENGEL

  • Research Location

    United States of America

  • Lead Research Institution

    LEIDOS BIOMEDICAL RESEARCH, INC.

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Phase 2 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase II

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

  • Mpox Research Priorities

    Vaccines research, development and implementation

  • Mpox Research Sub Priorities

    Development of equitable, accessible, safe and effective vaccines

Abstract

This study is a Phase 2 randomized, open-label, non-placebo controlled, multi-site clinical trial that will evaluate two intradermal (ID) regimens for Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine compared to the standard subcutaneous (SC) regimen in healthy, vaccinia-naïve adults 18 to 50 years of age.